Hillevax stock rises after XOMA Royalty announces acquisition

Hillevax Inc. (HLVX) has entered a definitive merger agreement to be acquired by XOMA Royalty Corporation (XOMA) for $1.95 per share in cash, plus a non-transferable Contingent Value Right (CVR) offering potential additional payments tied to Hillevax's remaining cash, lease savings, and future proceeds from norovirus vaccine programs. The Hillevax Board unanimously approved the transaction, which is expected to close by September 2025, subject to customary conditions including majority share tender, with key stakeholders already committing 22.9% of shares. HLVX shares rose 2.9% on the news, reflecting market reception to the structured acquisition.

Analysis

Hillevax Inc. (HLVX) has entered a definitive merger agreement to be acquired by XOMA Royalty Corporation (XOMA) in a structured deal that prompted a 2.9% rise in HLVX shares. The transaction offers HLVX shareholders $1.95 in cash per share plus a non-transferable Contingent Value Right (CVR). This CVR represents potential future upside tied to three specific outcomes: a share of Hillevax's cash reserves exceeding $102.95 million, a percentage of savings from a Boston office lease, and 90% of net proceeds from the potential disposition of its norovirus vaccine programs within five years of regulatory approval. The deal carries a high probability of completion, evidenced by the unanimous approval from Hillevax's Board and a commitment from stakeholders holding 22.9% of common stock to tender their shares, which is a significant step toward reaching the required majority. The acquisition is slated for a relatively distant close in September 2025, a timeline that adds a temporal risk factor for investors. The positive sentiment score for HLVX (0.7) reflects the market's favorable view of the acquisition terms for the target, while the more neutral score for XOMA (0.2) suggests the market may be weighing the potential value of the acquired assets against the complex, long-term CVR liabilities.

Key Decisions for Investors

• Hillevax investors must assess the potential value of the CVR, as the total return on the transaction is heavily dependent on future, uncertain events including the monetization of the norovirus vaccine program and operational savings.
• Given the high degree of insider support and unanimous board approval, event-driven investors might find the deal's certainty attractive, but must weigh this against the extended timeline to a September 2025 close, which introduces significant time-value and market risk.
• XOMA investors should monitor the long-term financial impact of the CVR structure, as the acquirer's low sentiment score suggests market uncertainty regarding whether the future value of Hillevax's assets will justify the acquisition's cost and complexity.